Long term effects of olanzapine and betahistine on serotonin 5-HT2A receptor binding in the rat brain
RIS ID
80294
Abstract
Olanzapine is widely used in treating multiple domains of schizophrenia symptoms through its binding profiles to various neurotransmitter receptors including 5-HT2A receptors (5-HT2AR). Our previous studies have shown that 2 weeks co-treatment of betahistine (a H1R agonist and H3R antagonist) could reduce obesity induced by olanzapine. This study aimed to investigate whether long term co-treatment of olanzapine and betahistine affects 5-HT2AR bindings. Methods: Female Sprague- Dawley rats were administered under 4 conditions (n=12): (1) Rats were treated with vehicle (control) during whole experimental period; (2) Cotreatment group (O+B): 5 weeks olanzapine treatment (1 mg/kg, t.i.d.), followed by 6 weeks co-administration of olanzapine with betahistine (9.6 mg/kg, t.i.d.); (3) olanzapine only (1 mg/kg, t.i.d.) treatment during weeks 7-11; (4) betahistine only (9.6 mg/kg, t.i.d.) treatment during weeks 7-11. Density of 5-HT2AR were measured using [³H]ketanserin. Results: Compared to the controls, olanzapine significantly decreased 5-HT2AR bindings in accumbens shell and substantia nigra (SN) (p
Publication Details
Lian, J., Huang, X. -F. & Deng, C. 2013, 'Long term effects of olanzapine and betahistine on serotonin 5-HT2A receptor binding in the rat brain', 33rd Meeting of the Australian Neuroscience Society: Program, Abstracts & List of Registrants, ANS, Australia, pp. 171-171.